Literature DB >> 6589011

Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears.

G Tricot, C De Wolf-Peeters, B Hendrickx, R L Verwilghen.   

Abstract

Forty bone-marrow trephine biopsies of patients with myelodysplastic syndromes (MDS) were studied and compared with bone marrow smears. It proved possible to make the diagnosis of MDS on the basis of bone-marrow biopsies. Features of abnormal erythropoiesis and myelopoiesis, although different from those observed in smears, were easily detectable. Moreover, obvious advantages of bone-marrow biopsy over bone-marrow smears were found. Firstly, the biopsy in MDS gives an exact assessment of the cellularity; secondly, the presence of reticulin fibres, increased in the majority of the cases, can be evaluated; thirdly, dysmegakaryopoiesis is more easily detected in trephine biopsies than in smears; finally, abnormal behaviour of myeloblasts, clustering centrally in the bone marrow, is frequently observed before the smears show an excess of myeloblasts. The bone-marrow biopsy also has a role in difficult cases, where the diagnosis of MDS can not be established on just bone-marrow smears. The five types of MDS, as described by the FAB group, do not represent recognizable histological entities.

Entities:  

Mesh:

Year:  1984        PMID: 6589011     DOI: 10.1111/j.1365-2141.1984.tb02916.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

Review 1.  Bone marrow histology. 3: Value of bone marrow core biopsy in acute leukaemia, myelodysplastic syndromes, and chronic myeloid leukaemia.

Authors:  D A Winfield; S V Polacarz
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

2.  Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.

Authors:  J Thiele; H Quitmann; S Wagner; R Fischer
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

Review 3.  Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview.

Authors:  J Thiele; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

4.  Refractory myelodysplastic anaemias with hypocellular bone marrow.

Authors:  Y Yoshida; S Oguma; H Uchino; T Maekawa
Journal:  J Clin Pathol       Date:  1988-07       Impact factor: 3.411

5.  Techniques for obtaining differential cell counts from bone marrow trephine biopsy specimens.

Authors:  B S Wilkins; C J O'Brien
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

6.  Persistent injury-associated anemia and aging: Novel insights.

Authors:  Tyler J Loftus; Kolenkode B Kannan; Christy S Carter; Jessica M Plazas; Juan C Mira; Scott C Brakenridge; Christiaan Leeuwenburgh; Philip A Efron; Alicia M Mohr
Journal:  J Trauma Acute Care Surg       Date:  2018-03       Impact factor: 3.313

7.  Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance.

Authors:  D Marisavljević; Z Rolović; V Cemerikić; D Bosković; M Colović
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

8.  Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features.

Authors:  G E Verhoef; C De Wolf-Peeters; A Ferrant; S Deprez; P Meeus; M Stul; P Zacheé; J J Cassiman; H Van den Berghe; M A Boogaerts
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

9.  Abnormal localization of immature precursors (ALIP) detection for early prediction of acute myelocytic leukemia (AML) relapse.

Authors:  Hai-Qing Huang; Xiang-Zhong Fang; Jun Shi; Jie Hu
Journal:  Med Biol Eng Comput       Date:  2013-12-21       Impact factor: 2.602

10.  Haemopoietic regrowth after chemotherapy for acute leukaemia: an immunohistochemical study of bone marrow trephine biopsy specimens.

Authors:  B S Wilkins; A G Bostanci; M F Ryan; D B Jones
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.